RBC Capital Maintains Sector Perform on Agios Pharmaceuticals, Raises Price Target to $32

Benzinga Newsdesk www.benzinga.com Positive 91.5%

Neg 0% Neu 0% Pos 91.5%

RBC Capital analyst Luca Issi maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Sector Perform and raises the price target from $28 to $32.